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ABSTRACT
Background: Delayed leukoencephalopathy (DL) is a rare entity associated with cerebral hypoxia and heroin consumption. We describe the 
clinical course of three cases of DL due to non-heroin drug use.
Material and methods: We describe the cases of three DL patients admitted to our hospital in 2012.
Discussion: These cases contribute to the aetiological spectrum of DL since multifactorial causes could account for the clinical symptoms.
LEARNING POINTS
• Substances toxic to the CNS can damage the CNS directly (direct toxicity) or by depressing the respiratory centre (cerebral hypoxia).
• As clinical manifestations can appear after a time lag, we recommend a period of initial monitoring.
•	 Histological	and	radiological	findings	can	contribute	to	better	understanding	of	the	pathophysiological	mechanisms	and	causes	involved.
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BACKGROUND
Delayed leukoencephalopathy (DL) is caused by structural injury to the white matter of the central nervous system (CNS), with a characteristic 
two-phase clinical course: recovery from an episode of low level of awareness, caused by acute or chronic neurological damage, is followed 
by neuropsychiatric symptoms which include cognitive and level of consciousness disorders, behavioural disorders and dysautonomy. The 
disorder is associated with parkinsonism when grey matter basal nuclei are involved[1]. 
The condition was initially called delayed post-hypoxic leukoencephalopathy (DPHL) and correlated with causes of cerebral hypoxia, such 
as CO poisoning or respiratory depression due to asphyxia, constriction, drugs, etc.[2,3]. In DL, the grey matter basal nuclei are damaged by 
hypoxia[1], the posterior fossa structures are not affected, and there is increased permeability of the blood–brain barrier[4]. There is severe 
diffuse	demyelination,	but	the	subcortical	U-fibres	are	not	damaged,	and	neither	spongiosis	nor	vacuolation	occur[3]. The disease usually has 
a good prognosis.
Leukoencephalopathy following heroin pyrolysate inhalation predominantly affects the cerebellum and brainstem. The condition presents 
with two gradual clinical phases, without an intervening recovery period. During the initial stage the disease causes cerebellar ataxia, 
hyperactive	 deep	 tendon	 reflexes,	 hypertonic	 hemiplegia	 or	 tetraplegia,	 choreoathetoid	movements	 and	 pseudobulbar	 reflexes.	 In	 the	
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terminal	stage,	which	does	not	always	develop,	it	causes	central	pyrexia,	spasms,	hypotonic	paresis,	areflexia	and	akinetic	mutism.	Specific	
histological	findings	include	spongiform	degeneration	of	the	CNS	white	matter	with	vacuoles	and	cavities,	foci	of	necrosis	in	the	spongiform	
white matter and multivacuolar degeneration of the oligodendroglia and axons, all of which affect the hemispheres, cerebellum, brainstem 
and spinal cord[5].
Isolated cases with a similar neurological picture, attributable to consumption of methadone and other toxic substances (benzodiazepines, 
neuroleptics, barbiturates, etc.), demonstrating a low level of consciousness and possible associated hypoxia, have been reported[2]. 
We present the case reports below to increase knowledge of the aetiological spectrum of DL syndromes. A review of the literature on the 
subject is also provided. 
CASE REPORT
Case 1 was a 42-year-old male polydrug user (but no heroin use for over 5 years). After a methadone, alprazolam and alcohol overdose, he 
experienced an episode of low level of consciousness, respiratory depression and fever without clinical focus. Initial neuroimaging revealed 
non-specific	findings.
The patient’s consciousness level initially recovered but suddenly worsened 13 days later. During the following weeks, he remained febrile, 
with	spontaneous	resolution,	and	with	fluctuating	consciousness,	which	gradually	improved.	He	had	widespread	myoclonus.	Cranial	MRI	
(Fig. 1) revealed bilateral, symmetrical and diffuse involvement of the cerebral white matter, as well as bilateral globus pallidus injury. EEG 
revealed diffuse slowing of background neuronal activity. The patient remained stable. Lack of attention and dysexecutive and amnestic 
abnormalities persisted at discharge.
Case 2 was a 43-year-old man living with HIV treated with emtricitabine/tenofovir and lopinavir/ritonavir, HCV genotype 3 chronic liver 
disease and drug abuse (no heroin use for over 5 years). He was admitted after a methadone overdose with a low level of consciousness 
and a bradypnoea episode. This was associated with tachycardia and sweating, as well as fever without clinical focus, which resolved 
spontaneously. An initial cranial CT scan revealed decreased image density in both globus pallidi.
During	the	first	few	days,	the	patient	recovered	awareness	and	made	spontaneous	voluntary	movements.	He	reacted	by	opening	his	eyes	
when spoken to and answered with basic words. However, drowsiness, slow thinking and occasional agitation remained.
During the following days, the low level of awareness, sweating, tachypnoea and fever reappeared. Associated infection was not observed. 
A chest angio-CT ruled out pulmonary embolism. The patient did not speak, and presented spastic rigidity and an extensor motor response 
to pain. Neuroimaging revealed bilateral, symmetrical and diffuse involvement of the cerebral white matter, with clinical progression of the 
lesions in both globus pallidi (Fig. 2).	EEG	revealed	diffuse	slowing	of	background	neuronal	activity.	A	cerebrospinal	fluid	study	was	normal.	
The patient gradually deteriorated without recovering consciousness. Tachypnoea, fever and sweating remained. He died 40 days after the 
onset of symptoms.
Figure 1. Cranial MRI. (A) Hypointense lesions in both globus pallidi (arrows). (B) 
Bilateral symmetrical hyperintense white matter lesions (arrows)
Figure 2. (A, B) Cranial CT showing hyperintense lesions in globus pallidi (arrows) and 
a hypointense white matter lesion (arrowhead). (C) Cranial MRI showing hypointense 
lesions in globus pallidi, with peripheral hyperintense (arrow) and diffuse, bilateral and 
symmetrical hyperintense white matter lesions (arrowhead)
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Case 3 was a 52-year-old male polydrug user (no heroin use for over 5 years), living with HIV treated with emtricitabine/tenofovir and 
lopinavir/ritonavir and chronic liver disease secondary to HBV/HDV coinfection. He was admitted for abnormal behaviour, disorientation, 
inattention	and	low	level	of	consciousness	after	intoxication	with	venlafaxine	and	alprazolam.	There	were	no	findings	on	initial	cranial	CT.
Over	 the	 following	 days,	 the	 patient	 regained	 consciousness	 and	 stayed	 alert,	 inattentive	 and	with	 hyperreflexia.	 Brain	MRI	 revealed	
homogeneous, bilateral and symmetrical changesin the intensity of the cerebral white matter (Fig. 3). EEG showed slow background baseline 
activity.	There	were	no	abnormalities	in	the	cerebrospinal	fluid	study.
The patient gradually showed a better level of consciousness, maintained a coherent conversation and obeyed simple commands. He 
achieved independent gait. At discharge, he remained disoriented, with disturbed immediate memory and motor apraxia.
DISCUSSION
In all three cases reported, the patient underwent an episode of low level of consciousness, followed by initial improvement and then further 
development of leukoencephalopathy symptoms. This biphasic clinical course indicates all three patients had DL. Motor symptoms may 
follow globus pallidus injury, but were not present in case 3. Damage to the cerebral grey matter suggests cerebral hypoxia, which is a rare 
finding	in	the	pure	toxic	leukoencephalopathies[4].
These patients had not used heroin for at least 5 years and no cerebellar involvement was shown by the neuroimaging tests. Two of the three 
patients also experienced a recovery period between the two clinical phases of the disease, but this temporary recovery was not seen in the 
leukoencephalopathy caused by heroin inhalation[5].
The time lag between the two clinical phases of the disease could be due to oligodendrocyte injury, which prevents replacement of myelin in 
the CNS and causes late onset demyelination[3].
These case reports contribute to the possible aetiology of this rare disease, since the drugs involved can cause both direct brain toxicity 
and cerebral hypoxia through depression of the respiratory centre. The mentioned drugs should be included in the differential diagnosis of 
DL. Their mechanisms of action can cause both DPHL and delayed toxic leukoencephalopathy. It is also thought that both conditions can 
sometimes co-exist.
Figure 3. Cranial MRI showing (A) confluent, homogeneous, bilateral and symmetrical 
changes in the white matter (arrows) and (B) no involvement of the grey matter basal 
nuclei. 
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